NCT07326163

Brief Summary

This study was designed to evaluate the effect of topically applied peppermint oil (Mentha × piperita) on chronic pain and functional capacity experienced by fibromyalgia patients, as well as its cost-effectiveness.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
175

participants targeted

Target at P75+ for not_applicable

Timeline
8mo left

Started Mar 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress22%
Mar 2026Jan 2027

First Submitted

Initial submission to the registry

December 24, 2025

Completed
15 days until next milestone

First Posted

Study publicly available on registry

January 8, 2026

Completed
2 months until next milestone

Study Start

First participant enrolled

March 1, 2026

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2026

Expected
2 days until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2027

Last Updated

March 5, 2026

Status Verified

January 1, 2026

Enrollment Period

10 months

First QC Date

December 24, 2025

Last Update Submit

March 4, 2026

Conditions

Keywords

AromatherapyFibromyalgiaPainFunctional CapacityCost

Outcome Measures

Primary Outcomes (5)

  • Visual Analog Scale

    The visual analogue scale is a commonly used pain assessment tool due to its ease of application, reliability, and sensitivity. It consists of a horizontal line measuring 10 cm in length, with the left end labelled 'no pain' and the right end labelled 'severe pain'. The patient is asked to mark the point on this line that best represents their pain intensity, and then the distance between the patient's mark and the left end is measured. This distance, usually measured in millimetres, is interpreted as a 'score'.

    2 weeks

  • The short-form McGill Pain Questionnaire

    This scale consists of three sections; the first section contains 15 word groups for describing pain. Eleven of these words assess the sensory dimension of pain, while four assess the perceptual dimension. These descriptive words are rated on an intensity scale from 0 to 3 (0 = none, 1 = mild, 2 = moderate, 3 = severe). In the first section of the scale, a total of three pain scores are obtained: sensory pain score, perceptual pain score, and total pain score. The second section contains six word groups ranging from 'no pain' to 'unbearable pain' to determine the severity of the pain. In the third section, the patient's current pain intensity is assessed using a visual analogue scale.

    2 weeks

  • The Revised Fibromyalgia Impact Questionnaire (FIQR)

    The Fibromyalgia Impact Questionnaire consists of 21 separate questions. All questions are based on an 11-point numerical rating scale ranging from 0 to 10; 10 indicates the worst possible situation, while 0 means no complaint. The questionnaire consists of three subscales: function, overall impact, and symptoms. The function subscale contains 9 questions, the overall impact subscale contains 2 questions, and the symptoms subscale contains 10 questions. The total score obtained from the items related to function (range 0 to 90) is divided by 3, the total score for general impact (range 0 to 20) remains unchanged as it is divided by 1, and the total score for symptoms (range 0 to 100) is divided by 2 for calculation.

    2 weeks

  • Collection of Cost Data from the Perspective of the Reimbursement Agency (Social Security Institution)

    Costs from the perspective of the reimbursement agency for patients diagnosed with fibromyalgia who receive pharmacological treatment and treatment with aromatherapy oils will be determined through clinical, administrative, and financial records obtained from the hospital's billing, materials management, pharmacy, purchasing, information processing, and statistics departments. Each expense item related to treatments will be classified in detail through detailed invoice breakdowns obtained from the relevant units. Detailed expenditure items related to treatment methods will be expressed through tables.

    2 weeks

  • Collection of Cost Data from the Direct Patient Cost Perspective

    A questionnaire prepared using the literature will be used to determine costs from the direct patient cost perspective. Using this form, called the direct patient cost questionnaire, expenses such as consultation, aromatherapy oils, medication, transportation, nutrition, bed, accommodation and other items (clothing, cleaning supplies, etc.) will be collected for each patient. Tables showing all expense items will be prepared based on the cost data obtained.

    2 weeks

Study Arms (3)

peppermint oil

EXPERIMENTAL

This group of patients will be introduced to the tender points where chronic pain is detected in fibromyalgia patients, and the areas where these tender points are located will be divided into six regions, which will be identified with the patient. Subsequently, one drop of peppermint oil will be applied transdermally to the inner surface of the patient's forearm, and the application site will be monitored for allergic reactions such as redness or swelling. Patients who do not report any allergic reactions will apply 2 drops of peppermint oil to each area transdermally with their fingertip at 8:00 a.m. and 8:00 p.m. This application will be performed twice daily by the patient for 2 weeks. For areas inaccessible to the patient, a relative/caregiver will apply 2 drops of peppermint oil. The first dose will be administered by the researcher, who will demonstrate the application to the patient. The patient's opinions will be sought and questions answered during the first dose application

Other: Peppermint Oil

sweet almond oil

ACTIVE COMPARATOR

Patients in this group will be introduced to the six sensitive areas where pain is felt, and the locations will be identified with the patient. The patient will apply 2 drops of sweet almond oil to each sensitive area twice daily, at 8:00 a.m. and 8:00 p.m., using their fingertip. This application will be performed twice daily by the patient for 2 weeks. For sensitive areas that the patient cannot access, a family member/caregiver will apply 2 drops of sweet almond oil. The first dose will be administered by the researcher, who will demonstrate the application to the patient. The patient's opinions will be sought and their questions answered during the first dose administration. Sweet almond oil will be provided to patients in dark-coloured glass bottles with droppers and secure caps that open with firm pressure. Patients will be advised to store sweet almond oil at room temperature.

Other: sweet almond oil

Duloxetine

OTHER

Patients in this group will receive treatment planned by a rheumatologist. The pharmacological treatment plan will involve administering duloxetine 60 mg once daily for two weeks, a serotonin-noradrenaline reuptake inhibitor effective on descending pain inhibition pathways in fibromyalgia.

Other: Duloxetine

Interventions

This group of patients will be introduced to the tender points where chronic pain is detected in fibromyalgia patients, and the areas where these tender points are located will be divided into six regions, which will be identified with the patient. Subsequently, one drop of peppermint oil will be applied transdermally to the inner surface of the patient's forearm, and the application site will be monitored for allergic reactions such as redness or swelling. Patients who do not report any allergic reactions will apply 2 drops of peppermint oil to each area transdermally with their fingertip at 8:00 a.m. and 8:00 p.m. This application will be performed twice daily by the patient for 2 weeks. For areas inaccessible to the patient, a relative/caregiver will apply 2 drops of peppermint oil. The first dose will be administered by the researcher, who will demonstrate the application to the patient. The patient's opinions will be sought and questions answered during the first dose application

peppermint oil

Patients in this group will be introduced to the six sensitive areas where pain is felt, and the locations will be identified with the patient. The patient will apply 2 drops of sweet almond oil to each sensitive area twice daily, at 8:00 a.m. and 8:00 p.m., using their fingertip. This application will be performed twice daily by the patient for 2 weeks. For sensitive areas that the patient cannot access, a family member/caregiver will apply 2 drops of sweet almond oil. The first dose will be administered by the researcher, who will demonstrate the application to the patient. The patient's opinions will be sought and their questions answered during the first dose administration. Sweet almond oil will be provided to patients in dark-coloured glass bottles with droppers and secure caps that open with firm pressure. Patients will be advised to store sweet almond oil at room temperature.

sweet almond oil

Patients in this group will receive treatment planned by a rheumatologist. The pharmacological treatment plan will involve administering duloxetine 60 mg once daily for two weeks, a serotonin-noradrenaline reuptake inhibitor effective on descending pain inhibition pathways in fibromyalgia.

Duloxetine

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosed with fibromyalgia according to the 2010 American College of Rheumatology diagnostic criteria,
  • Experiencing chronic pain,
  • Volunteers to participate in the study,
  • Aged 18 years or older,

You may not qualify if:

  • Those with painful medical conditions other than fibromyalgia (e.g., migraine, diabetic neuropathy, etc.),
  • Those with a chronic respiratory system disease (history of asthma or another reactive airway disease),
  • Individuals with compromised skin integrity in the application areas,
  • Pregnant and/or breastfeeding women,
  • Individuals with neurocognitive impairment who are unable to answer the questionnaire,
  • Individuals with a known history of allergies,
  • Individuals using any topical products during the application period,
  • Individuals receiving other complementary treatments for chronic pain management.
  • Criteria for discontinuing the study:
  • Patients who continue their treatment at a different centre after being included in the study,
  • Patients who undergo any medication or treatment changes during the study period,
  • Patients who are bothered by the scent of the essential oils used (peppermint oil (Mentha × piperita) and sweet almond oil (Prunus amygdalus var. dulcis), or who develop an allergic reaction to essential oils.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Bilecik Training and Research Hospital

Bilecik, Bilecik, 11000, Turkey (Türkiye)

Location

MeSH Terms

Conditions

FibromyalgiaPain

Interventions

peppermint oilalmond oilDuloxetine Hydrochloride

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesRheumatic DiseasesNeuromuscular DiseasesNervous System DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

ThiophenesSulfur CompoundsOrganic ChemicalsHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Research Assistant

Study Record Dates

First Submitted

December 24, 2025

First Posted

January 8, 2026

Study Start

March 1, 2026

Primary Completion (Estimated)

December 30, 2026

Study Completion (Estimated)

January 1, 2027

Last Updated

March 5, 2026

Record last verified: 2026-01

Locations